References
- Huh JY, Panagiotou G, Mougios V et al. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism 61(12), 1725–1738 (2012).
- Gouni-Berthold I, Berthold HK, Huh JY, Berman R, Spenrath N, Krone W, Mantzoros CS. Effects of lipid-lowering drugs on irisin in human subjects in vivo and in human skeletal muscle cells ex vivo. PLoS ONE 8(9), e72858 (2013).
- Berthold HK, Naini A, Di Mauro S et al. Effect of ezetimibe and/or simvastatin on coenzyme Q10 levels in plasma: a randomized trial. Drug Saf. 29(8), 703–712 (2006).
- Bostrom P, Wu J, Jedrychowski MP et al. A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 481(7382), 463–468 (2012).
- Mikus CR, Boyle LJ, Borengasser SJ et al. Simvastatin impairs exercise training adaptations. J. Am. Coll. Cardiol. 62(8), 709–714 (2013).
- Goodpaster BH. Mitochondrial deficiency is associated with insulin resistance. Diabetes 62(4), 1032–1035 (2013).
- Kelly DP. Medicine. Irisin, light my fire. Science 336(6077), 42–43 (2012).